1951-Benefits of Step1 Info, Mr, Edward Man , Hong Kong 09,11,2011

8/4/2019 1951-Benefits of Step1 Info, Mr, Edward Man , Hong Kong 09,11,2011

1/19

Copy right AMS.USA 09.08.2011 we do NOT accept any changes, corrections.

American Medical Science, USA. 3327 La Seine LN Spring, TX 77388 USAE mail: [email protected] Tel. 281.288-0921 Fax: 443.200.6091 www.abcmilk.com


2/19

Indication

ABC STEP1 includes Prebiotics and is a milk-based, iron-fortified formula for full-term infants 012 months.

ABC STEP1 offers growth, brain and eye, and immunesystem development.




3/19

9/11/2011 3

Product Features ABC STEP1 Milk-based infant formula patterned after breast milk

2 prebiotics ingredientsgalactooligosaccharides and polydextroseto

support the growth of beneficial gut bacteria Bifidogenic effect similar to that of breast milk in infants fed the formula

between 30 and 90 days of age

Mother's milk contains high concentrations of lactose and lowerquantities of phosphate (pH Buffer). Therefore, when mother's milk isfermented by lactic acid bacteria (incl. bifidobacteria) in the infant's GI

tract, the pH may be reduced, making it more difficult for Gram-negative bacteria to grow.

Improve respiratory health through the first 3 years of life.

Growth similar to breastfed infants through 12 months, support for theimmune system

DHA,support mental, visual, and immune system development Easy-to-digest .




4/19

9/11/2011 4

Bifidogenic,

By , DR. M. SOK

Abstract

BACKGROUND: Human milk oligosaccharides have been

shown to stimulate selectively the growth of

Bifidobacteria and Lactobacilli in the intestine.In this study, the bifidogenic effect of anexperimental prebiotics oligosaccharidemixture consisting of low-molecular-weight

galactooligosaccharides and high-molecular-weight fructooligosaccharides was analyzedin 90 term infants.


5/19

9/11/2011 5

Bifidogenic,

By , DR. M. SOK

METHODS:

Two test formulas were supplemented witheither 0.4 g/dL or with 0.8 g/dLoligosaccharides. In the control formula,

Maltodextrin was used as placebo. At studyday 1 and study day 28, the fecal species,colony forming units (cfu) and pH were

measured and stool characteristics, growth,and side effects were recorded.


6/19

9/11/2011 6

Bifidogenic,

By , DR. M. SOK RESULTS: At study day 1, the median number of Bifidobacteria did not differ among the

groups (0.4 g/dL group, mean [interquartile range] 8.5 [1.9] cfu/g; 0.8 g/dLgroup, 7.7 [6.1] cfu/g; and the placebo group, 8.8 [6.1] cfu/g) (figures in squarebrackets are interquartile range). At the end of the 28-day feeding period, thenumber of Bifidobacteria was significantly increased for both groups receivingsupplemented formulas (the 0.4 g/dL group, 9.3 [4.9] cfu/g; the 0.8 g/dL group,9.7 [0.8] cfu/g) versus the placebo group (7.2 [4.9] cfu/g, P < 0.001). This effectwas dose dependent (0.4 g/dL versus 0.8 g/dL, P < 0.01). The number of

Lactobacilli also increased significantly in both groups fed the supplementedformulas (versus placebo, P < 0.001), but there was no statistically significantdifference between the group fed formula with 0.4 g/dL oligosaccharides and thegroup fed formula with 0.8 g/dL oligosaccharides. The dosage of supplementsignificantly influenced the change in fecal pH (P < 0.05) (placebo, pH 5.5-6.1;0.4 g/dL formula, pH 5.48-5.44; 0.8 g/dL formula, pH 5.54-5.19). Slight changesin the stool frequency resulted in a significant difference between the placebo

group and the group fed the 0.8 g/dL formula at day 28 (P < 0.01).Supplementation had a significant dose-dependent influence on stoolconsistency (0.8 g/dL versus placebo, P < 0.0001; 0.8 g/dL versus 0.4 g/dL, P

Documents

1951-Benefits of Step1 Info, Mr, Edward Man , Hong Kong 09,11,2011